scholarly journals The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer

2009 ◽  
Vol 22 (03) ◽  
Author(s):  
Song
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Mobility ◽  
Small Cell ◽  
High Mobility Group ◽  
Small Cell Lung ◽  
High Mobility Group Protein ◽  
Group Protein

Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer

2018 ◽  
Vol 21 (3) ◽  
pp. 547-555 ◽  
Author(s):  
Xiangjun Guo ◽  
Jiaxin Shi ◽  
Yan Wen ◽  
Mengmeng Li ◽  
Qin Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Mobility ◽  
Small Cell ◽  
High Mobility Group ◽  
Small Cell Lung ◽  
Node Metastasis

scholarly journals Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer

2009 ◽  
Vol 103 (12) ◽  
pp. 1949-1953 ◽  
Author(s):  
Guan-Hong Shang ◽  
Chong-Qi Jia ◽  
Hui Tian ◽  
Wei Xiao ◽  
Yu Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Mobility ◽  
Small Cell ◽  
High Mobility Group ◽  
Small Cell Lung ◽  
Clinical Marker

High-mobility group box 3 (HMGB3) silencing inhibits non-small cell lung cancer development through regulating Wnt/β-catenin pathway

2020 ◽  
Vol 401 (10) ◽  
pp. 1191-1198 ◽  
Author(s):  
Yunjing Li ◽  
Yongfu Ma ◽  
Tong Zhang ◽  
Changjiang Feng ◽  
Yang Liu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Mobility ◽  
Small Cell ◽  
High Mobility Group ◽  
Migration And Invasion ◽  
Small Cell Lung

AbstractIt has been reported that high-mobility group box 3 is overexpressed in various cancers. This study aimed to explore its function in non-small cell lung cancer (NSCLC). A546 and H460 cell lines were used for in vivo experiments, scratch healing tests, transwell migration and invasion experiments. It was first found that HMGB3 was highly expressed in tumor tissues in the patients and associated with NSCLC stage. Silencing of HMGB3 significantly slowed the growth, proliferation and invasion of NSCLC in vitro, and repressed cell growth in vivo. Mechanistic studies suggest that the observed effects were mediated by inhibiting the expression of β-catenin/MMP7/c-Myc in Wnt pathway. Our study highlights the role of HMGB3 in NSCLC, which may provide a therapeutic target for the treatment of NSCLC.

scholarly journals Tox2 is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Mobility ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Lower Expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding the thymyocyte selection-associated high mobility box protein family member 2 transcription factor Tox2 was among the genes whose expression was most quantitatively different in tumors from patients with NSCLC as compared to the lung. Tox2 expression was significantly decreased in NSCLC tumors as compared to the lung, and lower expression of Tox2 in patient tumors was significantly associated with worse overall survival. Tox2 may be important for initiation or progression of non-small cell lung cancer in humans.

Sign in / Sign up

Export Citation Format

Share Document